Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by mcarter4on Sep 25, 2003 8:33am
295 Views
Post# 6457296

RE: thoughts....

RE: thoughts....My concern of yesterdays events (sufficient that I unloaded half my shares). The PP seems very oddly timed and not reflective of any previous management statements. As various posters have indicated mngt has stated that after their last PP they had cash for 2 years. So I assume no overriding need for $'s. If mngt had waited for positive results a lot more $'s could be had with much less dilution. I will point you to my largest holding IDB. They did a US $25M placement in May, after positive results published and a +40 run up in share price. Then just did a 2nd PP for $US100M again after positive results published and a +50% run up in share price. Both mimimized dilution and fully within corporate plan and communications. It almost seems as if the mngt of ONC are somewhat unsure of their science. Secondly, cancelling two presentations in one day, how confusing is that. No specific rule, as far as I know, related the PP would have kept them from presenting. Not showcasing to a big US audience I see as a blunder. CrappXXX vs. UBS, not a very good trade off. While I don't doubt the ONC science, mngt. to me seems somewhat in need of upgrading. But hey in the long run who knows, maybe they only gave away a small portion of the potential, or maybe it was a great strategic move.
Bullboard Posts